8-K: Senti Bio Reports Q3 2025 Results, Confirms ASH Data Readout

Senti Biosciences announced its third-quarter 2025 financial results and confirmed an upcoming clinical data readout for its SENTI-202 study in AML at the American Society of Hematology Annual Meeting in December.

Summary

• Reported financial results for the third quarter ended September 30, 2025.
• Confirmed the next clinical data readout for the Phase 1 SENTI-202 study in Acute Myeloid Leukemia (AML) at the American Society of Hematology (ASH) Annual Meeting, scheduled for December 6-9, 2025, in Orlando, Florida.
• Cash and cash equivalents were approximately $12.2 million as of September 30, 2025, a significant decrease from $48.3 million as of December 31, 2024.
• Research and development expenses increased to $10.5 million for the three months ended September 30, 2025, compared to $8.7 million for the same period in 2024.
• General and administrative expenses decreased to $6.4 million for the three months ended September 30, 2025, from $6.6 million for the same period in 2024.
• Net loss was $18.1 million, or $0.69 per basic and diluted share, for the three months ended September 30, 2025, an improvement from a net loss of $28.866 million, or $6.31 per share, for the same period in 2024.
• The company is focused on driving SENTI-202 clinical development, executing on the dose expansion phase, and enrolling additional patients with relapsed/refractory AML at the Recommended Phase 2 Dose.

Sentiment

Score: 4

Explanation: The company reported progress in its SENTI-202 clinical trial with upcoming data presentations at ASH, which is a positive scientific milestone. However, the financial results show a significant decrease in cash and cash equivalents, indicating a high burn rate and raising concerns about the company's liquidity and need for future capital.

Positives

• Confirmed upcoming presentation of updated clinical data for SENTI-202 at the American Society of Hematology (ASH) Annual Meeting in December, including additional patient data from a more recent data-cut.
• The presented data is expected to showcase continued efficacy, safety, and durability of SENTI-202, highlighting the ability of Logic Gate technology for selective cancer killing and healthy tissue sparing.
• Progress in the dose expansion phase and enrollment of additional relapsed/refractory AML patients at the Recommended Phase 2 Dose.
• Participation in several investor and scientific conferences to build market awareness and increase visibility.
• Net loss decreased to $18.1 million in Q3 2025 from $28.866 million in Q3 2024.
• Basic and diluted net loss per share decreased significantly to $0.69 in Q3 2025 from $6.31 in Q3 2024.

Negatives

• Significant decrease in cash and cash equivalents to $12.2 million as of September 30, 2025, from $48.3 million as of December 31, 2024, indicating a high cash burn rate.
• Research and development expenses increased by $1.8 million to $10.5 million for the three months ended September 30, 2025, compared to $8.7 million for the same period in 2024.
• Total assets decreased to $52.685 million as of September 30, 2025, from $97.841 million as of December 31, 2024.
• Total stockholders' equity decreased to $8.121 million as of September 30, 2025, from $25.649 million as of December 31, 2024.

Risks

• Changes in domestic and foreign business, market, financial, political, and legal conditions.
• Changes in the competitive and highly regulated industries in which Senti Bio operates, variations in operating performance across competitors, and changes in laws and regulations affecting Senti Bio's business.
• The ability to implement business plans, forecasts, and other expectations.
• The risk of downturns and a changing regulatory landscape in Senti Bio's highly competitive industry.
• Risks relating to the uncertainty of any projected financial information with respect to Senti Bio.
• Risks related to uncertainty in the timing or results of Senti Bio's clinical studies, patient enrollment, and GMP manufacturing startup activities.
• Senti Bio's dependence on third parties in connection with clinical trial startup, clinical studies, and GMP manufacturing activities.
• Risks related to delays and other impacts from macroeconomic and geopolitical events, increasing rates of inflation, and rising interest rates on business operations.
• Risks related to the timing and utilization of the grant from CIRM.
• The success of any future research and development efforts by Senti Bio.

Future Outlook

The company expects to present updated clinical data from additional patients with relapsed/refractory AML who have received SENTI-202 at the upcoming ASH Annual Meeting in December, showcasing continued efficacy, safety, and durability. Management is focused on driving SENTI-202 clinical development forward, executing on the dose expansion phase, and enrolling additional patients at the Recommended Phase 2 Dose.

Management Comments

• "Our team is laser focused on driving SENTI-202 clinical development forward."
• "With important milestones achieved in the third quarter, we continue to execute on our dose expansion phase and on enrolling additional patients with relapsed/refractory AML at the Recommended Phase 2 Dose."
• "At the upcoming ASH Annual Meeting in December, we will be presenting exciting clinical data from additional patients with R/R AML who have received SENTI-202, showcasing continued efficacy, safety, and durability."
• "This data will highlight the ability of our Logic Gate technology to achieve selective cancer killing and healthy tissue sparing, which overcomes a central challenge in the treatment of cancer."
• "We are pleased with the progress made to date and look forward to discussing our expanded dataset next month."

Industry Context

Senti Bio operates in the highly competitive and regulated clinical-stage biotechnology sector, specifically focusing on next-generation cell and gene therapies using its proprietary Gene Circuit platform. The company's focus on Logic Gate technology to achieve selective cancer killing and healthy tissue sparing addresses a critical challenge in oncology, positioning it within the innovative segment of cancer treatment development. The upcoming ASH presentation is a standard and important event for biotech companies to present clinical progress and gain visibility within the scientific and investment communities.

Related Party Transactions

• Research and development expenses include related party costs of $3.417 million for the three months ended September 30, 2025, and $3.790 million for the three months ended September 30, 2024.
• GeneFab sublease income (expense) related party was $(1.567) million for the three months ended September 30, 2025, and $1.657 million for the three months ended September 30, 2024.
• Change in fair value of GeneFab Option related party was $2.386 million for the three months ended September 30, 2025.
• Change in fair value of GeneFab Economic Share related party was $(398) thousand for the three months ended September 30, 2025.
• Change in fair value of GeneFab Note Receivable related party was $(17.435) million for the three months ended September 30, 2025.

Stakeholder Impact

• Shareholders: Potential for increased volatility due to upcoming clinical data and significant cash burn. High risk of dilution from potential future capital raises to fund operations.
• Patients: Continued progress in the SENTI-202 clinical trial offers hope for new treatment options for Acute Myeloid Leukemia, a challenging disease.
• Employees: Ongoing R&D activities and clinical development suggest continued work, but the company's deteriorating financial health could pose long-term concerns regarding job security and operational stability.
• Creditors/Suppliers: The company's declining cash position and overall financial health may impact its ability to meet future obligations or secure favorable terms with creditors and suppliers.

Next Steps

• Present updated clinical data from additional patients with R/R AML who have received SENTI-202 at the American Society of Hematology (ASH) Annual Meeting in Orlando, Florida, from December 6-9, 2025.
• Host a live webcast during the ASH meeting to discuss the results.
• Continue to execute on the dose expansion phase and enroll additional patients with relapsed/refractory AML at the Recommended Phase 2 Dose for the SENTI-202 study.

Key Dates

Recommendation

While the upcoming clinical data for SENTI-202 at ASH is a positive scientific development, the company's financial position is highly concerning. Cash and cash equivalents have plummeted to $12.2 million, representing a substantial burn rate. This level of cash is insufficient to sustain operations for an extended period, especially for a clinical-stage biotech, strongly indicating an imminent need for a dilutive capital raise. The significant decrease in total assets and stockholders' equity further underscores the deteriorating financial health. Despite an improved net loss per share, the overall financial stability is weak, making the stock a high-risk investment with significant downside potential from dilution.

Keywords

Senti Biosciences, SNTI, biotechnology, cell therapy, gene therapy, Gene Circuit platform, AML, Acute Myeloid Leukemia, SENTI-202, clinical trial, Phase 1, ASH, financial results, Q3 2025, oncology, synthetic biology, Logic Gate technology